Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elravie Balance is a monophasic dermal filler and skin booster formulated with 23 mg/ml of hyaluronic acid and 0.3% lidocaine. Developed by the South Korean company Humedix, it utilizes proprietary High Intensity (HI) crosslinking technology to create a stable gel structure that maximizes bonds between hyaluronic acid and BDDE. It is primarily indicated for biorevitalization and skin rehabilitation, targeting signs of aging such as fine lines, wrinkles, and loss of skin volume by restoring hydration and structural support to the extracellular matrix. In clinical research, it has been used as a comparator for evaluating the efficacy of acellular dermal matrix-based skin boosters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Elravie Balance (Humedix).